ESG

Hopes for a new Huntington's gene therapy face a major delay as the FDA rejects uniQure's current data and calls for a more rigorous, complex study.

A new survey reveals alarming rates of depression and anxiety among Quebec parents, yet vital community support services remain largely unknown and unused.

HVAC giant AAON reports record 2025 sales but lower earnings due to massive investments. A $1.83B backlog signals a powerful 2026 rebound.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

A new technology promises to turn 35 years of Alaskan mine waste into gold and silver, heralding a new era of sustainable metal production.

Epson unveils a suite of printers, scanners, and projectors at HIMSS 2026, aiming to reduce errors, streamline workflows, and boost patient safety.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

Hudbay's acquisition of Arizona Sonoran creates a massive copper district, aiming to fuel the US green transition amid market jitters and local scrutiny.

An 8-month-old infant weighing just 5.5 kg receives a new liver from his father in a daring surgery, marking a milestone for pediatric care in India.

At the India AI Impact Summit, experts warned that AI crises will move at machine speed. Can global diplomacy and safety protocols catch up before it's too late?

At MWC 2026, MaxLinear showcases a single-chip solution enabling smaller, greener 5G radios, tackling key hurdles in the promising Open RAN market.

TCL announces its award-winning NXTPAPER 70 Pro is coming to the US, boasting a revolutionary paper-like display designed to combat digital eye strain.

Central Pattana's massive expansion aims to transform Phuket into a year-round luxury hub. But can the island's infrastructure and environment keep pace?

As PT SMI celebrates 17 years and a Rp1,183 trillion project portfolio, a government mandate for 'sharper impact' will define its next chapter.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

With its new AI thriller, muVpix is betting on 'engineered storytelling' to finally crack the vertical video code that doomed giants like Quibi.

Healthpeak Properties is launching a new senior housing REIT, Janus Living. What does this strategic pivot mean for investors and the real estate market?

A landmark donation accelerates NUNM's campus growth, promising a new integrative medicine center to meet the soaring demand for holistic healthcare.

Biotech firm NurExone showcases its CNS injury platform at key conferences, but the exit of its US subsidiary's CEO casts a shadow on growth plans.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.